Research To Practice | Oncology Videos

Inside the Issue: Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast Cancer | Faculty Presentation 2: Current and Future Role of Nonbiomarker-Based Strategies for Patients with Metastatic BRCA-Negative TNBC — Hope S Rugo, MD CME information and select publications

Inside the Issue: Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast Cancer | Faculty Presentation 1: Biomarker-Based Decision-Making for Patients with Metastatic BRCA-Negative, Triple-Negative Breast Cancer (TNBC) — Tiffany A Traina, MD, FASCO CME information and select publications

Featuring perspectives from Dr Hope S Rugo and Dr Tiffany Traina, including the following topics: Introduction: "Isn't Oncology Depressing?" (0:00) Checkpoint Inhibitors (13:37) Antibody-Drug Conjugates (30:04) HER2-Low Disease (54:25) Other Agents Under Development (59:54) CME information and select publications

Featuring an interview with Dr Paul G Richardson, including the following topics: Biologic rationale for targeting protein degradation pathways as a therapeutic approach in multiple myeloma (MM); mechanism of action of CELMoDs (0:00) Similarities and differences between iberdomide, mezigdomide and standard immunomodulatory drugs (7:14) Compassionate use of melflufen and belantamab mafodotin (12:08) Current management strategies for newly diagnosed MM (16:30) DETERMINATION: Evaluation of trial findings on racial and ethnic disparities and differential outcomes (23:02) Tailoring of up-front daratumumab-based therapies; management of extramedullary disease (33:17) CME information and select publications

Featuring a slide presentation and related discussion from Dr Paul G Richardson, including the following topics: Biologic rationale for targeting protein degradation pathways as a therapeutic approach in multiple myeloma (MM); mechanism of action of CELMoDs (0:00) Published efficacy and safety findings with iberdomide-containing combination regimens from the Phase I/II CC-220-MM-001 study (6:30) Emerging data with mezigdomide/dexamethasone for relapsed/refractory MM (13:22) Early results with and ongoing investigations of mezigdomide/dexamethasone in combination with a proteasome inhibitor (29:54) CME information and select publications

Featuring an interview with Dr Debra Richardson, including the following topics: Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors (0:00) Activity, safety and ongoing investigation of tumor treating fields in combination with chemotherapy for advanced ovarian cancer (5:12) ASCO and SGO guidance on the nationwide shortages of carboplatin and cisplatin (9:21) Investigating mechanisms of resistance to PARP inhibitors; potential use of circulating tumor DNA as an investigational tool (14:13) CME information and select publications

Featuring a slide presentation and related discussion from Dr Debra Richardson, including the following topics: Targeting folate receptor alpha in ovarian cancer; activity, tolerability and ongoing investigation of the antibody-drug conjugate (ADC) mirvetuximab soravtansine (0:00) Other ADCs under investigation for patients with ovarian cancer (20:05) Mechanism of action and activity of upifitamab rilsodotin (UpRi) for patients with pretreated ovarian cancer (23:27) Emerging strategies for patients with platinum-resistant ovarian cancer (29:53) Rationale for the discontinuation of clinical development of UpRi (33:17) CME information and select publications

Featuring perspectives from Dr Nicole Lamanna and Dr William G Wierda, including the following topics: Introduction: Mentoring Fellows (0:00) Case: A woman in her mid 50s with multiple cardiovascular comorbidities and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) receives bendamustine/rituximab induction followed by venetoclax/rituximab consolidation in a clinical trial — Spencer Henick Bachow, MD (11:47) Case: A man in his late 70s with relapsed del(11q) CLL develops atrial fibrillation while receiving ibrutinib — Warren S Brenner, MD (18:15) Case: A man in his early 70s with CLL develops rash and bruising while receiving ibrutinib — Gigi Chen, MD (27:02) Case: A man in his late 80s with CLL receives acalabrutinib as initial therapy and experiences thrombocytopenia — Kapisthalam (KS) Kumar, MD (31:42) Case: A woman in her mid 80s with relapsed CLL (TP53 mutation) discontinues ibrutinib due to bruising — Dr Brenner (40:08) Case: A man in his early 80s with R/R mantle cell lymphoma discontinues ibrutinib due to bleeding risks after a traumatic head injury — Dr Bachow (49:01) Case: A man in his late 50s with CLL and response to acalabrutinib develops worsening myalgias a year later — Eric H Lee, MD, PhD (58:36) CME information and select publications

Inside the Issue: Optimizing the Management of Metastatic Pancreatic Cancer | Faculty Presentation 1: Selection and Sequencing of Therapy for Metastatic Pancreatic Cancer CME information and select publications

Optimizing the Management of Metastatic Pancreatic Cancer | Faculty Presentation 2: Current and Future Role of Biomarker-Based Decision-Making for Metastatic Pancreatic Cancer CME information and select publications